Paraneoplastic neurological syndromes: upgraded approaches to diagnosis
https://doi.org/10.30629/2658-7947-2024-29-1-4-13
Abstract
Paraneoplastic neurological syndromes (PNNS) are neurological disorders due to autoimmune attack on the nervous system, induced by a tumor remote from these structures. The existence of relatively stable associations between the neurological syndrome, the type of antineuronal antibodies (Ab) and the nature of tumor has been proven. At the same time, there are no pathognomonic combinations of this kind: the same antibodies can be detected in diff erent types of tumors and in diff erent syndromes. In addition, level of reliability of the diagnosis of PNNS is considered, taking into account the phenotype of the neurological disorder, the presence of certain antibodies in the blood serum, the verifi cation of oncopathology and the duration of the observation for the patient.
About the Authors
V. N. Grigoryeva
FSBEI of HE “Privolzhsky Research Medical University” of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Nizhny Novgorod, 603950
E. A. Ruina
FSBEI of HE “Privolzhsky Research Medical University” of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Nizhny Novgorod, 603950
References
1. Devine M.F., Kothapalli N., Elkhooly M., Dubey D. Paraneoplastic neurological syndromes: clinical presentations and management. Ther Adv Neurol Disord. 2020;14:1–19. doi: 10.1177/1756286420985323
2. Binks S., Uy C., Honnorat J., Irani S.R. Paraneoplastic neurological syndromes: a practical approach to diagnosis and management. Pract Neurol. 2022;22(1):19–31. doi: 10.1136/practneurol-2021-003073
3. Gilligan M., McGuigan C., McKeon A. Paraneoplastic neurologic disorders. Curr Neurol Neurosci Rep. 2023;23(3):67–82. doi: 10.1007/s11910-023-01250-w
4. Jitprapaikulsan J., Paul P., Thakolwiboon S., Mittal S.O., Pittock S.J., Dubey D. Paraneoplastic neurological syndrome: an evolving story. Neurooncol Pract. 2021;8(4):362–374. doi: 10.1093/nop/npab002
5. Shah S., Flanagan E.P., Paul P., Smith C.Y., Bryant S.C., Devine M.F., Lennon V.A., McKeon A., Pittock S.J., Dubey D. Population-Based Epidemiology Study of Paraneoplastic neurologicsyndromes. Neurol Neuroimmunol Neuroinfl amm. 2021;9(2):e1124. doi: 10.1212/NXI.0000000000001124
6. Sechi E., Flanagan E.P. Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and approaches to diagnosis and management. Front Neurol. 2021;12:673339. doi: 10.3389/fneur.2021.673339
7. Chung C., Allen E., Umoru G. Paraneoplastic syndromes: a focus on pathophysiology and supportive care. Am J Health Syst Pharm. 2022;79(22):1988–2000. doi: 10.1093/ajhp/zxac211
8. Sardiña González C., Martínez Vivero C., López Castro J. Paraneoplastic syndromes review: the great forgotten ones. Crit Rev Oncol Hematol. 2022;174:103676. doi: 10.1016/j.critrevonc.2022.103676
9. Joubert B., Rostásy K., Honnorat J. Immune-mediated ataxias. Handb Clin Neurol. 2018;155:313–332. doi: 10.1016/B978-0-444-64189-2.00021-4
10. Mitoma H., Manto M., Hadjivassiliou M. Immune-mediated cerebellar ataxias: clinical diagnosis and treatment based on immunological and physiological mechanisms. J Mov Disord. 2021;14(1):10–28. doi: 10.14802/jmd.20040
11. Vogrig A., Gigli G.L., Segatti S., Corazza E., Marini A., Bernardini A., Valent F., Fabris M., Curcio F., Brigo F., Iacono D., Passadore P., Rana M., Honnorat J., Valente M. Epidemiology of paraneoplastic neurological syndromes: a population-based study. J Chen Z., Liang Y., Yang H., Cao L., Zhou Y., Zhao Y., Zhang Y. Anti-CV2/CRMP5 antibody-positive paraneoplastic neurological syndromes with chronic intestinal pseudo-obstruction in a small-cell lung cancer patient: a case report and literature review. J Int Med Res. 2020;48(12):300060520974466. doi: 10.1177/030Neurol. 2020;267(1):26–35. doi: 10.1007/s00415-019-09544-1
12. Yan J., Chen Z., Liang Y., Yang H., Cao L., Zhou Y., Zhao Y., Zhang Y. Anti-CV2/CRMP5 antibody-positive paraneoplastic neurological syndromes with chronic intestinal pseudo-obstruction in a small-cell lung cancer patient: a case report and literature review. J Int Med Res. 2020;48(12):300060520974466. doi: 10.1177/0300060520974466
13. Hebert J., Riche B., Vogrig A., Muniz-Castrillo S., Joubert B., Picard G., Rogemond V., Psimaras D., Alentorn A., Berzero G., Desestret V., Rabilloud M, Honnorat J. Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France. Neurol Neuroimmunol Neuroinfl amm 2020;7:e883. https://doi.org/10.1212/NXI.0000000000000883
14. Sun X., Tan J., Sun H., Liu Y., Guan W., Jia J., Wang Z. AntiSOX1 antibodies in paraneoplastic neurological syndrome. J Clin Neurol. 2020;16(4):530–546. doi: 10.3988/jcn.2020.16.4.530
15. Graus F., Vogrig A., Muñiz-Castrillo S., Antoine J.G., Desestret V., Dubey D., Giometto B., Irani S.R., Joubert B., Leypoldt F., McKeon A., Prüss H., Psimaras D., Thomas L., Titulaer M.J., Vedeler C.A., Verschuuren J.J., Dalmau J., Honnorat J. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinfl amm. 2021;8(4):e1014. doi: 10.1212/NXI.0000000000001014
16. Kunchok A., McKeon A., Zekeridou A., Flanagan E.P., Dubey D., Lennon V.A., Klein C.J., Mills J.R., Pittock S.J. Autoimmune/ paraneoplastic encephalitis antibody biomarkers: frequency, age, and sex associations. Mayo Clin Proc. 2022;97(3):547–559. doi: 10.1016/j.mayocp.2021.07.023
17. Frykman H., Kumar P. An opinion on the clinical laboratory testing following the new 2021 PNS-Care diagnostic criteria. J Appl Lab Med. 2022;7(1):367–372. doi: 10.1093/jalm/jfab154
18. Loehrer P.A., Zieger L., Simon O.J. Update on paraneoplastic cerebellar degeneration. Brain Sci. 2021;11(11):1414. doi: 10.3390/brainsci11111414
19. Davydovskaya M.V., Boĭko A.N., Beliaeva I.A., Martynov M.Iu., Gusev E.I. Autoimmune encephalitis. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2015;115(4):95–101. (In Russ.)]. doi: 10.17116/jnevro20151154195-101
20. Dubey D., Wilson M.R., Clarkson B., Giannini C., Gandhi M., Cheville J., Lennon V.A., Eggers S., Devine M.F., MandelBrehm C., Kryzer T., Hinson S.R., Khazaie K., Hales C., Kattah J., Pavelko K.D., Andrews P., Eaton J.E., Jitprapaikulsan J., Mills J.R., Flanagan E.P., Zekeridou A., Leibovich B., Fryer J., Torre M., Kaufman C., Thoreson J.B., Sagen J., Linnoila J.J., DeRisi J.L., Howe C.L., McKeon A., Pittock S.J. Expanded clinical phenotype, oncological associations, and immunopathologic insights of paraneoplastic Kelch-like protein-11 encephalitis. JAMA Neurol. 2020;77(11):1420–1429. doi: 10.1001/jamaneurol.2020.2231
21. Dubey D., Jitprapaikulsan J., Bi H., Do Campo R.V., McKeon A., Pittock S.J., Engelstad J.K., Mills J.R., Klein C.J. AmphiphysinIgG autoimmune neuropathy: a recognizable clinicopathologic syndrome. Neurology. 2019;93(20):e1873–e1880.doi: 10.1212/WNL.0000000000008472
22. Li L., Guo Y., Wang J. Detection of paraneoplastic antibodies and their signifi cance in paraneoplastic neurologic syndromes: a narrative review. Ann Transl Med. 2023;11(7):283. doi: 10.21037/atm-21-2434
23. Erdil Yucesoy E., Tunc H., Erdem S.N., Bozkurt S., Tuncer N. Limbic encephalitis with dual positivity. Cureus. 2023;15(6):e40399. doi: 10.7759/cureus.40399
24. Flanagan E.P., Geschwind M.D., Lopez-Chiriboga A.S., Blackburn K.M., Turaga S., Binks S., Zitser J., Gelfand J.M., Day G.S., Dunham S.R., Rodenbeck S.J., Clardy S.L., Solomon A.J., Pittock S.J., McKeon A., Dubey D., Zekeridou A., Toledano M., Turner L.E., Vernino S., Irani S.R. Autoimmune encephalitis/ misdiagnosis in adults. JAMA Neurol. 2023;80(1):30–39. doi: 10.1001/jamaneurol.2022.4251
25. Zoccarato M., Grisold W., Grisold A., Poretto V., Boso F., Giometto B. Paraneoplastic neuropathies: What’s new since the 2004 recommended diagnostic criteria. Front Neurol. 2021;12:706169. doi: 10.3389/fneur.2021.706169
26. Sokhatskaya Yu.M., Vaskova N.L., Subbotina D.R., Chistova I.V., Sulin K.A., Krasnoshlyk P.V., Gulyaev D.A. Anti-YO encephalitis: case report and literature review. MEDLINE.RU. 2022;23(48):792–800. (In Russ.)]. http://www.medline.ru/public/art/tom23/art48.html
27. Herdlevær I., Haugen M., Mazengia K., Totland C., Vedeler C. Paraneoplastic cerebellar degeneration: the importance of including CDR2L as a diagnostic marker . Neurol Neuroimmunol Neuroinfl amm. 2021;8(2):e963. doi: 10.1212/NXI.0000000000000963
28. Nuzhnyi E.P., Krasnov M.Yu., Moskalenko A.N., Fedotova E.Yu., Chekanova E.O., Illarioshkin S.N. Paraneoplastic cerebellar degeneration. Russian neurological journal. 2023;28(4):43–53. (In Russ.)]. https://doi.org/10.30629/2658-7947-2023-28-4-43-53
29. Greenlee J., Brashear H.R. The discovery of anti-Yo (Anti-PCA1) antibody in patients with paraneoplastic cerebellar degeneration: opening a window into autoimmune neurological disease. Cerebellum. 2023;22(4):531–533. doi: 10.1007/s12311-022-01446-9
30. Graus F., Dalmau J., Valldeoriola F., Ferrer I., Reñe R., Marin C., Vecht C.J., Arbizu T., Targa C., Moll J.W. Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin’s disease. J Neuroimmunol 1997;74(1–2):55–61. doi: 10.1016/s0165-5728(96)00205-6
31. Tazi R., Salimi Z., Fadili H., Aasfara J., Hazim A. Anti-Ri-associated paraneoplastic neurological syndrome revealing breast cancer: A case report. Cureus. 2022;14(1):e21106. doi: 10.7759/cureus.21106
32. Luque F.A., Furneaux H.M., Ferziger R., Rosenblum M.K., Wray S.H., Schold S.C.Jr., Glantz M.J., Jaeckle K.A., Biran H., Lesser M., Paulsen W.A., River M.E., Posner Dr J.B. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol. 1991;29(3):241–51. doi: 10.1002/ana.410290303
33. Maudes E., Landa J., Muñoz-Lopetegi A., Armangue T., Alba M., Saiz A., Graus F., Dalmau J., Sabater L. Clinical signifi cance of Kelch-like protein 11 antibodies. Neurol Neuroimmunol Neuroinfl amm. 2020;7(3):e666. doi: 10.1212/NXI.0000000000000666
34. Narayan R.N., McKeon A., Fife T.D. Autoimmune vestibulocerebellar syndromes. Semin Neurol. 2020;40(1):97–115. doi: 10.1055/s-0039-3402061
35. Ortega Suero G., Sola-Valls N., Escudero D., Saiz A., Graus F. Anti-Ma and anti-Ma2-associated paraneoplastic neurological syndromes. Neurologia (Engl Ed). 2018;33(1):18–27. doi: 10.1016/j.nrl.2016.05.010 Epub 2016 Jul 25.
36. Gadoth A., Kryzer T.J., Fryer J., McKeon A., Lennon V.A., Pittock S.J. Microtubule-associated protein 1B: novel paraneoplastic biomarker. Ann Neurol. 2017;81(2):266–277. doi: 10.1002/ana.24872
37. Saint-Martin M., Joubert B., Pellier-Monnin V., Pascual O., Noraz N., Honnorat J. Contactin-associated protein-like 2, a protein of the neurexin family involved in several human diseases. Eur J Neurosci. 2018;48(3):1906–1923. doi: 10.1111/ejn.14081
38. Boyko M., Au K.L.K., Casault C., de Robles P., Pfeff er G. Systematic review of the clinical spectrum of CASPR2 antibody syndrome. J Neurol. 2020;267(4):1137–1146. doi: 10.1007/s00415-019-09686-2
39. Evenseth L.S.M., Gabrielsen M., Sylte I. The GABAB receptor-structure, ligand binding and drug development. Molecules. 2020;25(13):3093. doi: 10.3390/molecules25133093
40. Shaye H., Stauch B., Gati C., Cherezov V. Molecular mechanisms of metabotropic GABAB receptor function. Sci Adv. 2021;7(22):eabg3362. doi: 10.1126/sciadv.abg3362
41. Pavlova O.V., Pavlov K.A., Murashko A.A., Gurina O.I., Shmukler A.B. NMDA receptors, anti-NMDA receptor antibodies and their role in psychiatric and neuroinfl ammatory disorders. Molekulyarnaya meditsina. 2021;19(1):3–10. (In Russ.)]. https://doi.org/10.29296/24999490-2021-01-01
42. Winklehner M., Bauer J., Endmayr V., Schwaiger C., Ricken G., Motomura M., Yoshimura S., Shintaku H., Ishikawa K., Tsuura Y., Iizuka T., Yokota T., Irioka T., Höftberger R. Paraneoplastic cerebellar degeneration with P/Q-VGCC vs Yo autoantibodies. Neurol Neuroimmunol Neuroinfl amm. 2022;9(4):e200006. doi: 10.1212/NXI.0000000000200006
43. Benoit J., Muñiz-Castrillo S., Vogrig A., Farina A., Pinto A.L., Picard G., Rogemond V., Guery D., Alentorn A., Psimaras D., Rheims S., Honnorat J., Joubert B. Early-stage ContactinAssociated Protein-like 2 limbic encephalitis. Neurol Neuroimmunol Neuroinfl amm. 2022;10(1):e200041. doi: 10.1212/NXI.0000000000200041
44. Braczkowski M., Soszyński D., Sierakowska A., Braczkowski R., Kufel K., Łabuz-Roszak B. Autoimmune encephalitis with antibodies: anti-NMDAR, anti-AMPAR, anti-GQ1b, antiDPPX, anti-CASPR2, anti-LGI1, anti-RI, anti-Yo, anti-Hu, antiCV2 and anti-GABAAR, in the course of psychoses, neoplastic diseases, and paraneoplastic syndromes. Diagnostics (Basel). 2023;13(15):2589. doi: 10.3390/diagnostics13152589
45. Nguyen L., Wang C. Anti-NMDA receptor autoimmune encephalitis: diagnosis and management strategies. Int J Gen Med. 2023;16:7–21. doi: 10.2147/IJGM.S397429
46. Uy C.E., Binks S., Irani S.R. Autoimmune encephalitis: clinical spectrum and management. Pract Neurol. 2021;21(5):412–423. doi: 10.1136/practneurol-2020-002567
47. Budhram A., Leung A., Nicolle M.W, Burneo J.G. Diagnosing autoimmune limbic encephalitis. CMAJ. 2019;191(19):E529–E534. doi: 10.1503/cmaj.181548
48. Ding J.B., Dongas J., Hu K., Ding M. Autoimmune limbic encephalitis: a review of clinicoradiological features and the challenges of diagnosis. Cureus. 2021;13(8):e17529. doi: 10.7759/cureus.17529
49. Marsili L., Marcucci S., LaPorta J., Chirra M., Espay A.J., Colosimo C. Paraneoplastic neurological syndromes of the central nervous system: pathophysiology, diagnosis, and treatment. Biomedicines. 2023;11(5):1406. doi: 10.3390/biomedicines11051406
50. Klötzsch C., Böhmert M., Hermann R., Teegen B., Rentzsch K., Till А. Anti-Homer-3 antibodies in cerebrospinal fl uid and serum samples from a 58-year-old woman with subacute cerebellar degeneration and diff use breast adenocarcinoma. Neurol. Res. Pract.2022;4(1):29. https://doi.org/10.1186/s42466-022-00194-9
51. Martins L., Galvão D., Silva A., Vieira B., Reis Ó., Vitorino R., Pires P. Paraneoplastic opsoclonus-myoclonus syndrome as a rare presentation of breast cancer. J Surg Case Rep. 2019;2019(2):rjy365. doi: 10.1093/jscr/rjy365
52. Kostoglou A., Vlastos D., Bakalis A., Ghosh D. Breast cancer-associated opsoclonus-myoclonus syndrome: a case report. World J Surg Oncol. 2021;19(1):328. doi: 10.1186/s12957-021-02436-7
53. Sanadze A.G., Sidnev D.V., Tumurov D.A. Seronegative nonparaneoplastic Lambert–Eaton myasthenic syndrome. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2017;117(5):77–80. (In Russ.)]. https://doi.org/10.17116/jnevro20171175177-80
54. Hong B.Y., An H.J., Lim S.H. Long-standing Lambert-Eaton Myasthenic Syndrome Caused by Undetectable Small-Cell Lung Cancer: why we should follow-up LEMS. Diagnostics (Basel). 2022;12(7):1542. doi: 10.3390/diagnostics12071542
55. Panchenko N.I., Shuleshova N.V., Rudenko D.I., Skulyabin D.I., Kolchev S.A., Perfi lev S.V., Lapin S.V. Autoimmune аnti-NMDA encephalitis associated with the new coronavirus infection COVID-19. Russian neurological journal. 2023;28(4):60–67. (In Russ.)]. https://doi.org/10.30629/2658-7947-2023-28-4-60-67
56. Chefdeville A., Treilleux I., Mayeur M.E., Couillault C., Picard G., Bost C., Mokhtari K., Vasiljevic A., Meyronet D., Rogemond V., Psimaras D., Dubois B., Honnorat J., Desestret V. Immunopathological characterization of ovarian teratomas associated with anti-N-methyl-D-aspartate receptor encephalitis. Acta Neuropathol Commun. 2019;7(1):38. doi: 10.1186/s40478-019-0693-7
57. Muñiz-Castrillo S., Joubert B., Elsensohn M.H., Pinto A.L., Saint-Martin M., Vogrig A., Picard G., Rogemond V., Dubois V., Tamouza R., Maucort-Boulch D., Honnorat J. Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features. J Neurol Neurosurg Psychiatry. 2020;91(10):1076–1084. doi: 10.1136/jnnp-2020-323226
58. Dade M., Berzero G., Izquierdo C., Giry M., Benazra M., Delattre J.Y., Psimaras D., Alentorn A. Neurological syndromes associated with anti-GAD antibodies. Int J Mol Sci. 2020;21(10):3701. doi: 10.3390/ijms21103701
59. Zhang C., Dai Y., Han B., Peng J., Ma J., Tang Q., Yang L. A case of anti-GAD 65 autoimmune encephalitis associated with focal segmental stiff -person syndrome. Brain Sci. 2023;13(2):369. doi: 10.3390/brainsci13020369
60. Parillo M., Quattrocchi C.C., Pilato F., Di Lazzaro V., Beomonte Zobel B. Whole-body computed tomography as fi rst-line imaging procedure to exclude cancer in patients with neurological suspicion of paraneoplastic syndromes: shall clinical practice adhere to recommendations? Radiography (Lond). 2023;29(1):8–13. doi: 10.1016/j.radi.2022.09.001
Review
For citations:
Grigoryeva V.N., Ruina E.A. Paraneoplastic neurological syndromes: upgraded approaches to diagnosis. Russian neurological journal. 2024;29(1):4-13. (In Russ.) https://doi.org/10.30629/2658-7947-2024-29-1-4-13
Views:
1062
Email this article 